Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Negative PR-Negative HER2-Negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT02137837
What this trial is testing

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 37
Early research (Phase 1)Looking for participantsNCT06400472
What this trial is testing

Sofe-M in Participants With Selected Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company 575
Not applicableUnknownNCT05099978
What this trial is testing

Asian Multicenter Prospective Study of ctDNA Sequencing

Who this might be right for
Cervical CancerOvarian Clear Cell CarcinomaNasopharyngeal Carcinoma+3 more
National Cancer Center, Japan 506
Testing effectiveness (Phase 2)Study completedNCT02018458
What this trial is testing

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Who this might be right for
Breast Cancer
Baylor Research Institute 10
Early research (Phase 1)Ended earlyNCT06264921
What this trial is testing

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorSolid Tumor, AdultAdvanced Solid Tumor+26 more
NiKang Therapeutics, Inc. 23
Testing effectiveness (Phase 2)Looking for participantsNCT07045311
What this trial is testing

JS207 Combination Therapy in Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd. 80
Testing effectiveness (Phase 2)Ended earlyNCT05300958
What this trial is testing

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sun Yat-sen University 25
Testing effectiveness (Phase 2)Ended earlyNCT03184558
What this trial is testing

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Who this might be right for
Triple Negative Breast CancerInflammatory Breast Cancer Stage IV
BerGenBio ASA 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06724263
What this trial is testing

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Who this might be right for
Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical Cancers+4 more
Tasly Biopharmaceuticals Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06225284
What this trial is testing

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

Who this might be right for
Triple Negative Breast CancerPremenopausal Breast Cancer
National Taiwan University Hospital 124
Testing effectiveness (Phase 2)Active Not RecruitingNCT02750358
What this trial is testing

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Who this might be right for
Breast CancerEarly StageTriple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center 50
Early research (Phase 1)Study completedNCT03207529
What this trial is testing

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+15 more
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05888831
What this trial is testing

BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 100
Large-scale testing (Phase 3)Study completedNCT02555657
What this trial is testing

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Who this might be right for
Metastatic Triple Negative Breast Cancer
Merck Sharp & Dohme LLC 622
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Very early researchLooking for participantsNCT04265872
What this trial is testing

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Who this might be right for
Breast Cancer
Baylor Research Institute 20
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Next Page